Figure 4From: The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial designAmputation Free Survival over 1 year BMAC vs. Control (Rutherford 5 patients only) displays. The separation of AFS curves demonstrates a tread towards a positive effect of BMAC on AFS (p = 0.123). As in Figure 1, the event rate in Rutherford 4 patients was low, diluting any apparent treatment effect.Back to article page